JP2024543345A - Ｍｄｓ関連貧血及び他の状態を処置するための化合物 - Google Patents

Ｍｄｓ関連貧血及び他の状態を処置するための化合物 Download PDF

Info

Publication number
JP2024543345A
JP2024543345A JP2024526836A JP2024526836A JP2024543345A JP 2024543345 A JP2024543345 A JP 2024543345A JP 2024526836 A JP2024526836 A JP 2024526836A JP 2024526836 A JP2024526836 A JP 2024526836A JP 2024543345 A JP2024543345 A JP 2024543345A
Authority
JP
Japan
Prior art keywords
weeks
subject
compound
pharma
mds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526836A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543345A5 (https=
Inventor
ヴァネッサ ベイノン，
スマン ジョイ パティア，
レニー ダン，
メリッサ エル． ディバッコ，
ヴァーシャ ブイ． アイエル，
チャールズ クン，
メーガン リンチ，
オフィーリア チピン イン，
ロランダス アーブストナイティス，
ジェン シャオ，
Original Assignee
アジオス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アジオス ファーマシューティカルズ， インコーポレイテッド filed Critical アジオス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2024543345A publication Critical patent/JP2024543345A/ja
Publication of JP2024543345A5 publication Critical patent/JP2024543345A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2024526836A 2021-11-16 2022-11-15 Ｍｄｓ関連貧血及び他の状態を処置するための化合物 Pending JP2024543345A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163280069P 2021-11-16 2021-11-16
US63/280,069 2021-11-16
US202263357240P 2022-06-30 2022-06-30
US63/357,240 2022-06-30
PCT/US2022/049969 WO2023091414A1 (en) 2021-11-16 2022-11-15 Compounds for treating mds-associated anemias and other conditions

Publications (2)

Publication Number Publication Date
JP2024543345A true JP2024543345A (ja) 2024-11-21
JP2024543345A5 JP2024543345A5 (https=) 2025-11-26

Family

ID=84887868

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526836A Pending JP2024543345A (ja) 2021-11-16 2022-11-15 Ｍｄｓ関連貧血及び他の状態を処置するための化合物

Country Status (11)

Country Link
US (1) US20250108049A1 (https=)
EP (1) EP4433057A1 (https=)
JP (1) JP2024543345A (https=)
KR (1) KR20240107326A (https=)
AU (1) AU2022390088A1 (https=)
CA (1) CA3236880A1 (https=)
CL (1) CL2024001431A1 (https=)
IL (1) IL312679A (https=)
MX (1) MX2024005852A (https=)
TW (1) TW202329935A (https=)
WO (1) WO2023091414A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202509043A (zh) * 2023-05-15 2025-03-01 美商阿吉歐斯製藥公司 ２－（（１ｈ－吡唑－３－基）甲基）－６－（（６－胺基吡啶－２－基）甲基）－４－甲基－４，６－二氫－５ｈ－噻唑基［５＇，４＇：４，５］吡咯并［２，３－ｄ］嗒𠯤－５－酮之結晶形式
WO2026076363A1 (en) 2024-10-04 2026-04-09 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI598337B (zh) 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
CA2989111C (en) 2015-06-11 2023-10-03 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
TWI796353B (zh) 2017-08-15 2023-03-21 美商阿吉歐斯製藥公司 丙酮酸激酶調節劑及其用途
KR102777452B1 (ko) 2017-11-22 2025-03-10 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태
WO2020237047A1 (en) 2019-05-22 2020-11-26 Agios Pharmaceuticals, Inc. Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Also Published As

Publication number Publication date
CA3236880A1 (en) 2023-05-25
EP4433057A1 (en) 2024-09-25
TW202329935A (zh) 2023-08-01
CL2024001431A1 (es) 2024-10-25
US20250108049A1 (en) 2025-04-03
AU2022390088A1 (en) 2024-05-09
MX2024005852A (es) 2024-05-28
WO2023091414A1 (en) 2023-05-25
KR20240107326A (ko) 2024-07-09
IL312679A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
JP6852073B2 (ja) 悪性病変を処置する方法
KR102400737B1 (ko) 치료적으로 활성인 화합물의 약제학적 조성물
JP2021181478A (ja) 貧血治療のための組成物及び方法
AU2016340087C1 (en) Combination therapy for treating malignancies
TW202521120A (zh) 藥物組合物及其應用
TW201601727A (zh) 治療固態腫瘤之方法
UA123400C2 (uk) Комбінована терапія для лікування злоякісних пухлин
JP2023109974A (ja) 三置換ベンゾトリアゾール誘導体の使用方法
US20250108049A1 (en) Compounds for treating mds-associated anemias and other conditions
TWI866427B (zh) 雌激素受體降解劑之給藥方案
EP3137073A1 (en) Glyt1 inhibitors for use in the treatment of hematological disorders
AU2025271046A1 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
CN103429239A (zh) 增加网织红细胞血红蛋白含量的方法
JP2024536328A (ja) Ｐｔｐｎ１１阻害剤とｋｒａｓ ｇ１２ｃ阻害剤を用いた併用療法
CA3096156A1 (en) Use of inhibitors of bcr-abl mutants for the treatment of cancer
KR101741281B1 (ko) 건선 치료를 위한 ａ3 아데노신 수용체 작동약 (ｉｂ-ｍｅｃａ/ｃｆ-101)을 포함하는 제약학적 조성물
JP7493503B2 (ja) Ｍｃｌ－１阻害剤とミドスタウリンとの組み合わせ、その使用及び医薬組成物
EA050684B1 (ru) Соединения для лечения анемий и других патологических состояний, ассоциированных с mds
TW202440116A (zh) 組合療法
CN118382439A (zh) 用于治疗mds相关贫血和其他病症的化合物
CN118678960A (zh) 用于治疗癌症的方法和组合物
WO2026076363A1 (en) Compounds for treating mds-associated anemias and other conditions
RU2818453C2 (ru) Комбинация ингибитора mcl-1 и мидостаурина, ее применения и фармацевтические композиции
TW202404599A (zh) 使用經取代之嘧啶-4(3h)-酮及納武單抗(nivolumab)之組合療法
KR20220101148A (ko) 암의 치료를 위한 소아용 제제

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251114